NanoString Blog
Category: Miscellaneous
Miscellaneous nCounter
Common questions in molecular biology: How many types of cell counters are there?
Although it appears to be a simple question, there are several answers to “how many types of cell counters are there?” depending on how the word “type” is defined. Defining…
Digital Spatial Profiling Miscellaneous
Stories of Remarkable Technological Advances at AGBT 2020
The Advances in Genome Biology and Technology conference celebrated its 20th-anniversary event this February, and what a dramatic range of advances have occurred in our field since the first meeting!…
Digital Spatial Profiling Miscellaneous
SITC 2019 may be over, but the era of Spatial Genomics enabled by the GeoMx Digital Spatial Profiler has just begun.
The curtains have fallen on SITC 2019—the 34th annual meeting organized by the Society for Immunotherapy of Cancer—but excitement amongst the participants remains high after five days of knowledge exchange…
Digital Spatial Profiling Miscellaneous Oncology
Meet NanoString Scientists at the AMP 2019 Annual Meeting & Expo
When Elaine Lyon, Ph.D., a scientist on the board of the Association for Molecular Pathology (AMP) was asked why she is involved with AMP, its activities and initiatives, she quoted…
Digital Spatial Profiling Miscellaneous
A day (or two) with the Experts: the 2019 EU NanoString Summits Crosstalk
Since 2017 NanoString has hosted day-long summits in some of the liveliest and most charming European locations, where scientists and key opinion leaders have had the opportunity to share with…
Miscellaneous
Highlights from SITC 2017
It’s been an exciting and productive annual meeting for the Society for Immunotherapy of Cancer (SITC) 2017, full of ground-breaking science to share when back in the lab. For those…
Miscellaneous Oncology
Presidents, Rock Stars and Companion Diagnostics: 2016 Review of Immunotherapy
President Jimmy Carter announced this spring that he no longer needed treatments for the metastatic melanoma found in his brain–after treatment with pembrolizumab (Keytruda, Merck), his physicians could no longer…